Incannex receives irb approval for the reposa phase 2/3 clinical trial protocol to assess ihl-42x drug in patients with obstructive sleep apnea

Melbourne, australia and new york, jan. 17, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (‘incannex' or the ‘company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent institutional review board (irb) has approved the protocol for the company's phase 2/3 clinical trial to be conducted in the united states to assess safety and efficacy of proprietary combination drug candidate ihl-42x in patients with obstructive sleep apnea (osa). irb approval of the protocol is a key step in activation of clinical trial sites for the reposa study.
IXHL Ratings Summary
IXHL Quant Ranking